-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
-
Tools for Smoking Cessation
By Erik J. MacLaren, PhD Posted: October 2017 Scott Gottlieb, MD, Commissioner of the U.S. Food and Drug Administration, said in a recent speech, “There’s probably no single intervention or product we’re likely to create in the near future that can have as profound an impact on reducing illness and death from disease as our…
-
Deric Savior, MD
Posted: October 2017 Deric Savior, MD, has been appointed Head of Medical Oncology, Fox Chase Cancer Center at Temple University Hospital (TUH). Prior to this appointment, Dr. Savior led the Fox Chase thoracic oncology section at TUH, Philadelphia, USA, where he has served on the Cancer Committee, Institutional Review Board, Diversity Committee, and in the…
-
Second Annual Lung Cancer Awareness Month to Publicize Research Advances and Hope
By Keightley Amen, BA, ELS Posted: October 2017 This November, survivors around the world will celebrate the second annual Lung Cancer Awareness Month (LCAM) Consortium. Together, they will celebrate a unique, new initiative that spreads hope and shares progress in the fight against lung cancer. Led by IASLC, a rapidly growing partnership of advocacy groups…
-
Jean-Charles Soria, MD, PhD
Posted: October 2017 Jean-Charles Soria, MD, PhD, has been appointed Senior Vice President, Head of Oncology Innovative Medicines at MedImmune, AstraZeneca. He will oversee research, translational sciences and early drug development in oncology within MedImmune. Prior to this appointment, Dr. Soria served as a Professor of Medicine and Medical Oncology at South-Paris University. He was…
-
A Surprising Career Advances Cancer Research: Margaret Foti, MD, PhD (hc)
Posted: October 2017 When Margaret Foti began a job as an editorial assistant for the journal Cancer Research, with a communications degree and a fervor for the biological sciences, she could not have known then that she had just launched a remarkable, meaningful, and particularly impactful decades-long career. Just 4 years after her entry into…
-
Adjuvant Gefitinib Extended Disease-Free Survival in Patients With Stage II/IIIA Non-Small Cell Lung Cancer With EGFR-Activating Mutations
By Julien Mazieres, MD, PhD Posted: October 2017 The standard of care for patients postresection for lung cancer is adjuvant chemotherapy, usually a platinum-based regimen.1 The deciphering of lung oncogenesis has led to the routine use of targeted therapy in metastatic lung cancer but, to date, the use of these agents in the adjuvant setting…
-
Adjuvant Gefitinib Extended Disease-Free Survival in Patients With Stage II/IIIA Non-Small Cell Lung Cancer With EGFR-Activating Mutations
By Cynthia L. Kryder, MS, CCC-Sp Editor Note: IASLC Lung Cancer News is pleased to provide the following overview, which is followed by expert commentary by Dr. Heather Wakelee, Dr. Yi-Long Wu, and Dr. Julien Mazières. In patients with resected stage II-IIIA non-small cell lung cancer (NSCLC), cisplatin-based adjuvant chemotherapy over the last decade has…
-
Breaking News Briefs
• Alectinib received FDA priority review designation for first-line treatment of patients with ALK-positive, locally advanced or metastatic NSCLC. The supplemental new drug application included results from the phase III ALEX and J-ALEX studies, which were designed to evaluate alectinib as first-line treatment for patients with ALKpositive, locally advanced or metastatic NSCLC as detected by…
-
Frances A. Shepherd, OC, OOnt, MD, FRCPC
Posted: October 2017 Frances A. Shepherd, OC, OOnt, MD, FRCPC, is the recipient of two recent oncology awards: She received the Tenth Annual Addario Foundation Keynote Lecture Award, which recognizes luminaries in the lung cancer field working to improve and prolong the lives of those with the disease, and its eradication. In addition, Dr. Shepherd…
-
Raymond Osarogiagbon, MBBS, FACP
Raymond Osarogiagbon, MBBS, FACP, incoming chair of IASLC’s membership committee, will receive the 2017 Association of Community Cancer Centers Clinical Research Award. This award is given in recognition of research that has significantly and positively impacted the oncology patient, family, and community. Dr. Osarogiagbon is director of the Multidisciplinary Thoracic Oncology Program at the Baptist…